MDM2

Cat. No.

A18712

CAS No.

2136247-12-4

MD-224

MD-224 is a first-in-class and highly potent small-molecule human murine double minute 2 (MDM2) degrader based on the proteolysistargeting chimera (PROTAC) concept. MD-224 has the potential to be a new class of anticancer agent.

Cat. No.

A18877

CAS No.

2249750-24-9

PROTAC MDM2 Degrader-4

PROTAC MDM2 Degrader-4 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-4 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

Cat. No.

A18883

CAS No.

2249750-23-8

PROTAC MDM2 Degrader-3

PROTAC MDM2 Degrader-3 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-3 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

Cat. No.

A18890

CAS No.

2249944-99-6

PROTAC MDM2 Degrader-2

PROTAC MDM2 Degrader-2 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-2 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

Cat. No.

A18897

CAS No.

2249944-98-5

PROTAC MDM2 Degrader-1

PROTAC MDM2 Degrader-1 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-1 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

Cat. No.

A24731

CAS No.

2136246-72-3

MD-222

MD-222 is a first-in-class PROTAC degrader targeting MDM2. This compound contains ligands for both Cereblon and MDM2, facilitating the rapid degradation of MDM2 protein and subsequent activation of wild-type p53 in cellular contexts. Due to its mechanism of action, MD-222 exhibits notable anticancer properties, making it a valuable tool for research in cancer biology and therapeutic development.

Cat. No.

A30156

CAS No.

2713618-08-5

Seldegamadlin

Synonyms: KT-253

Seldegamadlin is a selective p53 stabilizer and an MDM2 PROTAC degrader with a DC50 of 0.4 nM. It effectively inhibits the proliferation of RS4;11 cancer cells, demonstrating an IC50 of 0.3 nM, and induces cell cycle arrest at the G2/M phase while promoting apoptosis. By upregulating p53 activity, Seldegamadlin overcomes the p53-MDM2 feedback loop, making it a valuable tool for research in hematologic and solid tumors, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Cat. No.

A53811

CAS No.

3049076-98-1

YX-02-030

YX-02-030 is a PROTAC MDM2 degrader that effectively inhibits the MDM2-p53 interaction with an IC50 value of 63 nM, as well as the VHL-HIF1α binding, with an IC50 of 1.35 μM. By binding to MDM2, it recruits the VHL E3 ubiquitin ligase, promoting MDM2 degradation. This compound is particularly relevant in researching therapeutic strategies against p53 mutant or deleted triple-negative breast cancer (TNBC) cells.

Cat. No.

A53880

CAS No.

2415160-21-1

MD-265

MD-265 is a potent MDM2 degrader utilizing the PROTAC (PROteolysis TArgeting Chimeras) technology. It effectively promotes the degradation of MDM2, resulting in the reactivation of the p53 tumor suppressor pathway in cancer cells with wild-type p53. Preclinical studies demonstrate that MD-265 induces complete tumor regression and enhances long-term survival in leukemia models, making it a valuable tool for cancer research and therapeutic development.

Cat. No.

A53881

CAS No.

2368944-44-7

WB156

WB156 is a dual degrader targeting MDM2 and GSPT1, facilitating their degradation through the recruitment of Cereblon (CRBN) to the ubiquitin-proteasome pathway. This compound effectively induces ubiquitination, leading to a reduction in MDM2 and GSPT1 levels, which is valuable for investigating the role of these proteins in cancer biology. WB156 holds potential for research applications in various cancer types, including leukemia.

Cat. No.

B10899

CAS No.

3049077-01-9

(4R,5S)-YX-02-030

(4R,5S)-YX-02-030 is a stereoisomer of YX-02-030, functioning as a PROTAC (Proteolysis Targeting Chimera) designed to promote the degradation of MDM2. This compound exhibits potent biological activity in disrupting MDM2-mediated degradation of p53, thereby enhancing p53 activity and providing insights into cancer therapy. Its application is particularly relevant in studies of tumor suppression and cellular signaling pathways involving MDM2 and p53 interactions.